INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10590896		
Filing Date		2006-08-28		
First Named Inventor	Tosh	ihiro USHIJIMA		
Art Unit		1645		
Examiner Name	Not Y	et Assigned		
Attorney Docket Number		USHIJIMA3		

					U.S.F	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	n to a	dd additional U.S. Pate	ent citatio	n informa	tion pl	ease click the	Add button.			
			U.S.P	ATENT A	APPLIC	CATION PUB	LICATIONS			
Examiner Initial*	aminer Cite No Publication Number Kind Code <sup>1</sup> Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1									
If you wis	h to a	u dd additional U.S. Pub	lished Ap	plication	citation	n information	please click the Ad	d butte	on.	
	5			FOREIG	N PAT	ENT DOCUM	MENTS			
Examiner Cite Foreign Document Country nitial* No Number³ Code² j				Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Т5		
	1									F
If you wis	h to a	dd additional Foreign F						butto	n .	1
		1				RATURE DO				
Examiner Initials*	Cite No	Include name of the a (book, magazine, jou publisher, city and/or	rnal, seri	ial, sympo	sium,	catalog, etc),			riate), title of the item ssue number(s),	T5

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10590896		
Filing Date		2006-08-28		
First Named Inventor Toshil		hiro USHIJIMA		
Art Unit		1645		
Examiner Name	Not Yet Assigned			
Attorney Docket Number		USHIJIMA3		

				1000	Total Control				
	1	Y. IMADA et al., "Enzyme-Linked Immunosorbent Assay Employing a Recombinant Antigen for Detection of Protecti Antibody against Swine Erysipelas", Journal of Clinical Microbiology, Vol. 41, No. 11, pp. 5015-5021, November 200							
	2		SIK et al., "Inclusion bodies from recombinant bacterial as a novel system for delivery of vaccine antigen by the ute", Immunology Letters, Vol. 91, pp. 197-204, 2004.						
	3		EEMANN et al., "Characterization of catalytic centre mutants of m earlson to Cys81Ser MIF", Eur. J. Biochem. Vol. 281, pp. 753-766,		nhibitory factor (MIF) and				
	4	S. A. KRUPENKO et al., "On the Role of Conserved Histidine 106 in 10-Formyltetrahydrofolate Dehydrogenase Catalysis", Journal of Biological Chemistry, Vol. 276, No. 26, pp. 24030-24037, June 29, 2001.							
	5	J. D. PHILLIPS et al., "Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase", Blood, Vol. 98, No. 12, pp. 3179-3185, December 1, 2001.							
	6	U. RINAS et al., "Cysteine to serine substitutions in basic fibroblast growth factor: effect on inclusion body formation and proteolytic susceptibility during in vitro refolding", BIO/TECHNOLOGY, Vol. 10, No. 4, pp. 435-440, 1992.							
	7 Supplementary European Search Report mailed July 11, 2008.								
If you wis	h to ac	dd add	litional non-patent literature document citation information p	lease click the Add b	outton				
			EXAMINER SIGNATURE						
Examiner Signature Date Considered									

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ² For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.